|

A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

RECRUITINGPhase 1/2Sponsored by Bristol-Myers Squibb
Actively Recruiting
PhasePhase 1/2
SponsorBristol-Myers Squibb
Started2026-09-15
Est. completion2029-10-30
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
Locations11 sites

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria

\- Adult participants with rheumatoid arthritis (RA) who meet definition of difficult-to-treat.

Exclusion Criteria

* Juvenile arthritis or onset of inflammatory arthritis before age 18.
* Seronegative RA participants in whom polymyalgia rheumatica has not been ruled out.
* Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Conditions2

ArthritisArthritis, Rheumatoid

Interventions1

Locations11 sites

Local Institution - 0068
La Jolla, California, 92037
Site 0068
Local Institution - 0070
Loma Linda, California, 92354
Site 0070
Local Institution - 0069
Palo Alto, California, 94304-2210
Site 0069
Local Institution - 0050
Aurora, Colorado, 80045
Site 0050
Colorado Blood Cancer Institute
Richard Nash, Site 0067303-981-2305

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.